---
figid: PMC5463420__12943_2017_670_Fig1_HTML
figlink: /pmc/articles/PMC5463420/figure/Fig1/
number: F1
caption: Schematic diagram of PI3K/Akt/mTOR signaling pathway and relevant PI3K inhibitors.
  When the growth factors bind to their corresponding RTKs, the regulatory isoform
  of PI3K (p85) binds to RTKs and relieves its inhibition on the catalytic isoform
  (p110), leading to the activation of PI3K. PI3K gives rise to the production of
  the lipid messenger PIP3 from PIP2, which can be reversed by the tumor suppressor
  PTEN. Subsequently, PIP3 binds to the PH domain of Akt and recruits Akt to the plasma
  membrane. PDK-1 is also recruited by PIP3 to the plasma membrane through its PH
  domain, and then phosphorylates Akt at Thr308. Akt is completely activated through
  phosphorylation at Ser473 by mTORC2 (PDK-2). PHLPP is able to dephosphorylate Akt
  at Ser473. Activated Akt phosphorylates a variety of downstream pathway molecules
  to facilitate tumor cell survival, proliferation, migration, invasion and glucose
  metabolism. The Akt downstream mTORC1 axis also regulates protein synthesis and
  cell growth. The tumor suppressor TSC1 and TSC2 are two substrates of Akt, and their
  phosphorylation leads to the blockade of their inhibitory effects on mTORC1. Activated
  mTORC1 then phosphorylates 4EBP1 and p70 S6 K, resulting in the initiation of protein
  translation. Activation of mTORC1 also triggers a negative feedback to suppress
  Akt phosphorylation. Numerous PI3K inhibitors have been developed to target PI3K/Akt/mTOR
  signaling. Pan-PI3K and isoform-selective PI3K inhibitors suppress the activities
  of p110 catalytic isoforms, while PI3K/mTOR inhibitors block the activation of both
  p110 and mTORC1/2
pmcid: PMC5463420
papertitle: 'Recent advances in the use of PI3K inhibitors for glioblastoma multiforme:
  current preclinical and clinical development.'
reftext: Hua-fu Zhao, et al. Mol Cancer. 2017;16:100.
pmc_ranked_result_index: '19422'
pathway_score: 0.9433114
filename: 12943_2017_670_Fig1_HTML.jpg
figtitle: PI3K/Akt/mTOR signaling pathway and relevant PI3K inhibitors
year: '2017'
organisms: Homo sapiens
ndex: b4bdfce6-df02-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5463420__12943_2017_670_Fig1_HTML.html
  '@type': Dataset
  description: Schematic diagram of PI3K/Akt/mTOR signaling pathway and relevant PI3K
    inhibitors. When the growth factors bind to their corresponding RTKs, the regulatory
    isoform of PI3K (p85) binds to RTKs and relieves its inhibition on the catalytic
    isoform (p110), leading to the activation of PI3K. PI3K gives rise to the production
    of the lipid messenger PIP3 from PIP2, which can be reversed by the tumor suppressor
    PTEN. Subsequently, PIP3 binds to the PH domain of Akt and recruits Akt to the
    plasma membrane. PDK-1 is also recruited by PIP3 to the plasma membrane through
    its PH domain, and then phosphorylates Akt at Thr308. Akt is completely activated
    through phosphorylation at Ser473 by mTORC2 (PDK-2). PHLPP is able to dephosphorylate
    Akt at Ser473. Activated Akt phosphorylates a variety of downstream pathway molecules
    to facilitate tumor cell survival, proliferation, migration, invasion and glucose
    metabolism. The Akt downstream mTORC1 axis also regulates protein synthesis and
    cell growth. The tumor suppressor TSC1 and TSC2 are two substrates of Akt, and
    their phosphorylation leads to the blockade of their inhibitory effects on mTORC1.
    Activated mTORC1 then phosphorylates 4EBP1 and p70 S6 K, resulting in the initiation
    of protein translation. Activation of mTORC1 also triggers a negative feedback
    to suppress Akt phosphorylation. Numerous PI3K inhibitors have been developed
    to target PI3K/Akt/mTOR signaling. Pan-PI3K and isoform-selective PI3K inhibitors
    suppress the activities of p110 catalytic isoforms, while PI3K/mTOR inhibitors
    block the activation of both p110 and mTORC1/2
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - RPTOR
  - AMELX
  - MTOR
  - MLST8
  - AKT1
  - PIK3CD
  - PIK3CG
  - MAPKAP1
  - TSC1
  - EIF4EBP1
  - PIK3R4
  - PTEN
  - AKT3
  - PIK3R6
  - PDK1
  - PHLPP1
  - PIK3R3
  - PIK3CB
  - PIK3R5
  - TSC2
  - SART3
  - RPS6KB1
  - RICTOR
  - PIK3CA
  - RPS6KB2
  - AKT2
  - BAY 80-6946
  - AMG319
  - ZSTK474
  - NVP-BEZ235
  - GDC-0941
  - PF-05212384
  - CH5132799
  - GSK2126458
  - GDC-0980
  - AZD6482
  - GDC-0032
  - Glucose
  - Ser
  - Cancer
genes:
- word: MTORC1
  symbol: mTORC1
  source: bioentities_symbol
  hgnc_symbol: RPTOR
  entrez: '57521'
- word: AMG
  symbol: AMG
  source: hgnc_prev_symbol
  hgnc_symbol: AMELX
  entrez: '265'
- word: MTORC1
  symbol: mTORC1
  source: bioentities_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: MLST8
  entrez: '64223'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K/MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: MAPKAP1
  entrez: '79109'
- word: TSC
  symbol: TSC
  source: bioentities_symbol
  hgnc_symbol: TSC1
  entrez: '7248'
- word: 4EBP1
  symbol: 4E-BP1
  source: hgnc_alias_symbol
  hgnc_symbol: EIF4EBP1
  entrez: '1978'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PDK-1
  symbol: PDK1
  source: hgnc_symbol
  hgnc_symbol: PDK1
  entrez: '5163'
- word: PHLPP
  symbol: PHLPP
  source: hgnc_prev_symbol
  hgnc_symbol: PHLPP1
  entrez: '23239'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: TSC
  symbol: TSC
  source: bioentities_symbol
  hgnc_symbol: TSC2
  entrez: '7249'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: p110
  symbol: p110
  source: hgnc_alias_symbol
  hgnc_symbol: SART3
  entrez: '9733'
- word: p70S6K
  symbol: P70S6K
  source: bioentities_symbol
  hgnc_symbol: RPS6KB1
  entrez: '6198'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: RICTOR
  entrez: '253260'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: p70S6K
  symbol: P70S6K
  source: bioentities_symbol
  hgnc_symbol: RPS6KB2
  entrez: '6199'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
chemicals:
- word: BAY 80-6946
  source: MESH
  identifier: C000589253
- word: AMG319
  source: MESH
  identifier: C000597234
- word: ZSTK474
  source: MESH
  identifier: C510150
- word: NVP-BEZ235
  source: MESH
  identifier: C531198
- word: GDC-0941
  source: MESH
  identifier: C532162
- word: PF-05212384
  source: MESH
  identifier: C549060
- word: CH5132799
  source: MESH
  identifier: C559137
- word: GSK2126458
  source: MESH
  identifier: C561454
- word: GDC-0980
  source: MESH
  identifier: C569670
- word: AZD6482
  source: MESH
  identifier: C578518
- word: GDC-0032
  source: MESH
  identifier: C582924
- word: Glucose
  source: MESH
  identifier: D005947
- word: Ser
  source: MESH
  identifier: D012694
diseases:
- word: Cancer
  source: ''
  identifier: ''
figid_alias: PMC5463420__F1
redirect_from: /figures/PMC5463420__F1
figtype: Figure
---
